ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced that Jim Hollingshead, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately.

Dr. Hollingshead is President of the Sleep business at ResMed (NYSE: RMD), a pioneer in cloud connected medical devices focused on the treatment of sleep related breathing disorders. He brings to the Insulet Board a unique combination of digital strategy and transformation expertise, as well as global corporate leadership and consulting experience in the biotech and life sciences sector. As the President of ResMed’s Sleep business, Dr. Hollingshead led ResMed’s transformation from a traditional medical hardware technology business to a SaaS-based digital solutions and services business, making ResMed a world-leading tech-driven medical device and software company. Under his leadership, ResMed’s Sleep business has dramatically expanded the scope and adoption of digital solutions in the treatment of sleep apnea around the globe and is pioneering the use of real world data and advanced analytics for the improvement of patient care.

“We are excited to welcome a leader with Jim’s expertise to the Insulet Board,” said Timothy Scannell, Chairman of Insulet’s Board of Directors. “Jim brings a track record of meaningful digital innovation and transformation in the medical device space, with deep experience in digitally-centric product development to not only better serve users, but expand growth opportunities. This experience is particularly relevant and complementary to Insulet, as we harness the power of technology and data to improve the lives of those living with diabetes.”

About Jim Hollingshead, Ph.D.:

Jim Hollingshead, Ph.D., is President of the Sleep business for ResMed, a global medical technology company with over nine million cloud-connectable devices for daily remote patient monitoring. From 2011 to 2017, Dr. Hollingshead held numerous positions at ResMed, including President, Americas, Chief Strategy Officer, and President, Ventures & Initiatives. Prior to joining ResMed, Dr. Hollingshead spent nearly two decades in strategy consulting across a wide range of industries including biotech, high-tech, and telecommunications. Previously, he was a senior partner in the Strategy and Life Sciences practices at Deloitte Consulting and also served as Managing Partner at Monitor Group, a U.S. strategy consulting firm, including serving in various global roles, including Founder and Managing Partner and European Marketing Strategy Practice in the U.K. and Office Managing Partner in Istanbul.

Dr. Hollingshead serves on the Board of SleepScore Labs, a joint venture between ResMed, Pegasus Capital and Oz Media. He holds a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University, and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

For more information, please visit: www.insulet.com and www.myomnipod.com.